Coherus Eyeing US Pegfilgrastim Bulk With On-Body Injector Approval
Amgen’s Onpro Version Commands the >40% Of The US Market
Coherus has roared into the new year with a US FDA approval that has long been on its radar: the company’s debut rival to the Neulasta Onpro on-body injector device using Coherus’ Udenyca (pegfilgrastim-cbqv) biosimilar.
